Advanced

Alzheimer's disease - Safety and dropout in long-term galantamine treatment in a routine clinical setting

Wallin, Åsa LU ; Wattmo, Carina LU and Minthon, Lennart LU (2007) 8th International Conference on Alzheimers and Parkinsons Diseases In New Trends in Alzheimer and Parkinson Related Disorders: ADPD 2007 p.245-249
Abstract
276 patients with Alzheimer's disease receiving galantamine in the Swedish Alzheimer Treatment Study were investigated for safety and dropout. Completion rates and reasons for dropout were monitored. The occurrence and time of death was investigated. Galantamine was well tolerated and few side effects were observed. The most frequent cause of dropout during the first year was side effects (n=9), the second and third year, because of adding memantine, which was overall the most frequent cause for dropout (28%). The observed death rate in the study population was not higher than in the average Swedish population (matched for age and gender). Completion-rates were high (51%) compared to previous 3-year studies of cholinesterase inhibitor... (More)
276 patients with Alzheimer's disease receiving galantamine in the Swedish Alzheimer Treatment Study were investigated for safety and dropout. Completion rates and reasons for dropout were monitored. The occurrence and time of death was investigated. Galantamine was well tolerated and few side effects were observed. The most frequent cause of dropout during the first year was side effects (n=9), the second and third year, because of adding memantine, which was overall the most frequent cause for dropout (28%). The observed death rate in the study population was not higher than in the average Swedish population (matched for age and gender). Completion-rates were high (51%) compared to previous 3-year studies of cholinesterase inhibitor treated patients. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Chapter in Book/Report/Conference proceeding
publication status
published
subject
in
New Trends in Alzheimer and Parkinson Related Disorders: ADPD 2007
pages
245 - 249
publisher
Medimond
conference name
8th International Conference on Alzheimers and Parkinsons Diseases
external identifiers
  • WOS:000257460200035
language
English
LU publication?
yes
id
e3d32cda-1ba8-4a63-9a9b-a496cce5beb4 (old id 1406792)
date added to LUP
2009-06-04 10:02:23
date last changed
2016-04-16 10:02:40
@misc{e3d32cda-1ba8-4a63-9a9b-a496cce5beb4,
  abstract     = {276 patients with Alzheimer's disease receiving galantamine in the Swedish Alzheimer Treatment Study were investigated for safety and dropout. Completion rates and reasons for dropout were monitored. The occurrence and time of death was investigated. Galantamine was well tolerated and few side effects were observed. The most frequent cause of dropout during the first year was side effects (n=9), the second and third year, because of adding memantine, which was overall the most frequent cause for dropout (28%). The observed death rate in the study population was not higher than in the average Swedish population (matched for age and gender). Completion-rates were high (51%) compared to previous 3-year studies of cholinesterase inhibitor treated patients.},
  author       = {Wallin, Åsa and Wattmo, Carina and Minthon, Lennart},
  language     = {eng},
  pages        = {245--249},
  publisher    = {ARRAY(0x84fdc68)},
  series       = {New Trends in Alzheimer and Parkinson Related Disorders: ADPD 2007},
  title        = {Alzheimer's disease - Safety and dropout in long-term galantamine treatment in a routine clinical setting},
  year         = {2007},
}